<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784433</url>
  </required_header>
  <id_info>
    <org_study_id>SOR478108CTIL</org_study_id>
    <nct_id>NCT00784433</nct_id>
  </id_info>
  <brief_title>The CArdiovasCulAr Diabetes &amp; Ethanol (CASCADE) Trial</brief_title>
  <acronym>CASCADE</acronym>
  <official_title>Cardiovascular and Metabolic Effects of Moderate Alcohol Consumption in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ben-Gurion University of the Negev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ben-Gurion University of the Negev</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Moderate alcohol may be beneficial for diabetics
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CVD status</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>alcohol 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>alcohol 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>alcohol</intervention_name>
    <description>150 cc</description>
    <arm_group_label>alcohol 1</arm_group_label>
    <arm_group_label>alcohol 2</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of type 2 diabetes

          -  Male or female alcohol abstainers (not more than 1 drink/week)

          -  Age between 40-75 yrs

          -  Clinically stable, with no history of stroke or myocardial infarction or major surgery
             within the previous 3 months

        Exclusion Criteria:

          -  The use of RI or short-acting analog insulin/ pump therapy. Patients on 1-2 injections
             per day of NPH or long-acting analogs will be eligible for inclusion

          -  Triglycerides &gt; 500 mg/dL

          -  HbA1c&lt;7 or &gt; 10%

          -  Serum creatinine &gt; 2 mg/dl

          -  Liver dysfunction (greater than 2-fold elevation of ALT or and 3-fold elevation of
             AST)

          -  Evidence of severe diabetes complications (such as proliferative retinopathy or overt
             nephropathy)

          -  Autonomic neuropathy manifested as postural hypotension or hypoglycemia unawareness

          -  Patients with chronic hepatitis (C,B)

          -  Use of drugs that might significantly interact with alcohol such as sedatives,
             antihistamines, and anti-coagulants

          -  Presence of active cancer, or chemotherapy within the past 3 years

          -  Major illness that may require hospitalization

          -  A high potential of addictive behavior based on physician's assessment or personal or
             family history of addiction, alcoholism, or alcohol abuse

          -  Pregnant or lactating woman

          -  Participation in another trial with active intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ben-Gurion University of the Negev</investigator_affiliation>
    <investigator_full_name>Iris Shai</investigator_full_name>
    <investigator_title>Iris Shai</investigator_title>
  </responsible_party>
  <keyword>alcohol diabetes CVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

